Cècile Schiffer-Mannioui

Title: Cècile Schiffer-Mannioui: Innovator in Cancer Immunotherapy

Introduction

Cècile Schiffer-Mannioui is a prominent inventor based in Villiers sur Marne, France. He has made significant contributions to the field of cancer immunotherapy, holding a total of four patents. His work focuses on developing innovative solutions to enhance the immune system's ability to target and destroy cancer cells.

Latest Patents

One of his latest patents is titled "Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy." This invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins designed to redirect immune cell specificity and reactivity toward selected membrane antigens. The extracellular ligand binding is derived from a 5T4 monoclonal antibody, which confers specific immunity against 5T4 positive cells. The engineered immune cells equipped with such CARs are particularly effective in treating lymphomas, leukemia, and solid tumors such as colon, stomach, and ovarian cancers.

Another significant patent is "Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy." This invention also involves CARs that redirect immune cell specificity and reactivity toward selected membrane antigens. The extracellular ligand binding in this case is derived from a GD3 monoclonal antibody, providing specific immunity against GD3 positive cells. The engineered immune cells with these CARs are well-suited for treating solid tumors like melanomas and carcinomas, as well as liquid tumors such as T-cell lymphoblastic leukemia.

Career Highlights

Cècile Schiffer-Mannioui works at Cellectis, a company known for its pioneering work in gene editing and immunotherapy. His expertise in developing CARs has positioned him as a key player in advancing cancer treatment methodologies. His innovative approaches have the potential to significantly improve patient outcomes in oncology.

Collaborations

Cècile collaborates with notable professionals in his field, including Julianne Smith. These collaborations enhance the research and development efforts at Cellectis, fostering an environment of innovation and discovery.

Conclusion

Cècile Schiffer-Mannioui is a distinguished inventor whose work in cancer immunotherapy is paving the way for new treatment options. His patents reflect a commitment to advancing medical science and improving the lives